文献
J-GLOBAL ID:201702229850279633
整理番号:17A1433305
自家幹細胞移植後の高リスクホジキンリンパ腫に対するブレンツキシマブ・ベドチンによる圧密の費用対効果分析【Powered by NICT】
Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation
著者 (13件):
Hui Lucy
(Yale School of Medicine, New Haven, Connecticut)
,
von Keudell Gottfried
(Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, Connecticut)
,
Wang Rong
(Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, New Haven, Connecticut)
,
Wang Rong
(Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut)
,
Zeidan Amer M.
(Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, Connecticut)
,
Zeidan Amer M.
(Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, New Haven, Connecticut)
,
Gore Steven D.
(Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, Connecticut)
,
Gore Steven D.
(Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, New Haven, Connecticut)
,
Ma Xiaomei
(Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, New Haven, Connecticut)
,
Ma Xiaomei
(Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut)
,
Davidoff Amy J.
(Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, New Haven, Connecticut)
,
Huntington Scott F.
(Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, Connecticut)
,
Huntington Scott F.
(Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, New Haven, Connecticut)
資料名:
Cancer (Hoboken, N.J.)
(Cancer (Hoboken, N.J.))
巻:
123
号:
19
ページ:
3763-3771
発行年:
2017年
JST資料番号:
D0781B
ISSN:
0008-543X
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
アメリカ合衆国 (USA)
言語:
英語 (EN)